Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07719322

Non Invasive Assessment of Subclinical Atherosclerosis and Cardiovascular Risk Using TYG Index in Lupus Nephritis

Systemic lupus erythematosus (SLE) is a chronic, multisystem autoimmune disease characterized by loss of immune tolerance, autoantibody production, immune complex deposition, and complement activation, resulting in widespread inflammation and organ damage. Renal involvement, known as lupus nephritis (LN), occurs in approximately 40-60% of SLE patients and represents one of the most severe disease manifestations, significantly contributing to morbidity and mortality.Lupus nephritis arises from immune complex deposition in glomerular and tubulointerstitial structures, causing inflammatory and proliferative lesions that can progress to chronic kidney disease or end-stage renal disease. The ISN/RPS classification provides a standardized histopathological framework essential for prognosis and guiding treatment decisions.

In addition to renal complications, patients with SLE and LN are at substantially increased risk of premature cardiovascular disease, which cannot be fully explained by traditional cardiovascular risk factors.Persistent systemic inflammation, endothelial dysfunction, dyslipidemia, and insulin resistance accelerate atherosclerosis in these patients. Subclinical vascular changes, including increased carotid intima-media thickness (CIMT) and carotid plaque formation, often precede overt cardiovascular events, underscoring the importance of early cardiovascular risk assessment The triglyceride-glucose (TyG) index is a validated surrogate marker of insulin resistance, correlating with endothelial dysfunction, subclinical atherosclerosis, and increased CIMT Elevated TyG index may therefore serve as a simple, non-invasive tool for early cardiovascular risk stratification in patients with lupus nephritis

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Systemic Lupus Erthematosus (SLE) Autoimmune Diseases Connective Tissue Diseases Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Glomerulonephritis Immune System Diseases Kidney Diseases Lupus Erythematosus, Systemic Lupus Nephritis Lupus Nephritis (LN) Male Urogenital Diseases Nephritis Skin and Connective Tissue Diseases Urogenital Diseases Urologic Diseases

Age range

19 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

About this study

the study is asingle center observational study will be conducted at Assiut University Hospital,Internal medicine departement, ,Rheumatology and Renal unit(inpatient,_outpatient clinics) including :Full history taking and thorough clinical examination including:

  • Demographic Information: Collect data on age, gender, duration of illness, and relevant medical history.
  • Body Mass Index (BMI)
  • smoking status and Medications history as (corticosteroids, immunosuppressants and anti lipidemic drugs to be excluded)
  • Clinical Assessment: patients diagnosed as SLE according to 2019 EULAR/ACR classification criteria. and lupus nephritis (LN) , classified according to the 2018 ISN/RPS classification of lupus nephritis.and Assessment of SLE disease activity according to SLEADI-2K score.
  • Laboratory Tests:
  • Combelete blood count (CBC)
  • Lipid profile ( fasting TGS ,total cholesterol, LDL, HDL, VLDL)
  • Fasting blood glucose (mg/Dl)
  • Kidney function test (Serum Creatinine ,blood urea nitrogen)
  • eGFR
  • CRP
  • Erthrocyte sedimentation rate (ESR)
  • Autoantibody Profiles: ANA, anti-dsDNA
  • Complement Levels: C3, C4
  • Urinary protein excretion (24-hour urinary protein )
  • Homocysteine
  • Serum uric acid
  • Renal biobsy
  • Indices calculation:
  • Triglyceride-Glucose (TyG) Index
  • The CRP_TYG index _- Carotid Ultrasonography

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adults aged ≥18 years
  • Diagnosis of SLE according to the 2019 ACR/EULAR classification criteria for systemic lupus erythematosus.
  • Lupus nephritis , classified according to the 2018 ISN/RPS classification of lupus nephritis.

Exclusion criteria

  • Established cardiovascular disease (MI, stroke, PAD)
  • Diabetes mellitus
  • Hypertension
  • Patient with CKD
  • infections
  • other autoimmune diseases
  • Pregnancy
  • Malignancy
  • chronic liver disease
  • Dyslipidemia
  • Obesity
  • Patients on lipid lowering therapy

Treatment and study plan

Primary outcomes

  1. 1.Determining whether TyG index independently predicts subclinical atherosclerosis after adjusting for traditional risk factors in patients of systemic lupus erythematosus (SLE) with or without lupus nephritis(LN).

    Time frame: baseline (at enrollment)

Study contacts

Contact information is provided by the study sponsor or research team.

nada abdelsalam nada abdelsalam hassan, MSc

CONTACT

[email protected]

+20 01003562354

Sponsors and collaborators

Lead sponsor

Assiut University

Other

Registry information

Official study title

Non Invasive Assessment of Subclinical Atherosclerosis in Relation to Triglyceride-Glucose (TyG) Index and Cardiovascular Risk in Lupus Nephritis a Single Center study_Assuit University

Important dates

Study start
2026
Primary completion
2028
Study completion
2029
First posted
Jul 22, 2026
Registry last updated
Jul 22, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.